Holen Sie sich die Stockscreener-App
31.46
0.25%
-0.08
Schlusskurs vom Vortag:
$31.54
Offen:
$31.54
24-Stunden-Volumen:
149.28K
Relative Volume:
0.49
Marktkapitalisierung:
$2.20B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-9.9046
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
-0.44%
1M Leistung:
+3.49%
6M Leistung:
+27.27%
1J Leistung:
+85.50%
1-Tages-Spanne:
$30.70
$32.28
1-Wochen-Bereich:
$30.49
$33.29
52-Wochen-Spanne:
$16.00
$33.33
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
31.46 | 2.20B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
PHVS Technical Analysis & Stock Price Forecast - Intellectia AI
Pharvaris (PHVS) CMO reports 109 shares withheld for RSU tax obligations - Stock Titan
Single capsule rapidly eased most HAE attacks in Pharvaris study - Stock Titan
Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026Slideshow - Seeking Alpha
Pharvaris (PHVS) Shows Modest Gains After Recent Pullback, Testing Key ResistanceSystematic Flow - newsline.com
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance - TipRanks
Pharvaris (Nasdaq: PHVS) details AGM plans and NDA timeline for HAE therapy - Stock Titan
Shareholders of Pharvaris to vote at June 26 annual meeting - Stock Titan
Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans - Sahm
Pharvaris N.V. (PHVS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in HAE Pipeline - newsline.com
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Insider Sell: Anna Nijdam Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) accounting officer sells 2,670 common shares on market - Stock Titan
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst - Sahm
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Anna Nijdam reports sales of PHVS common shares (PHVS) - Stock Titan
PHVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy ConferenceSlideshow (NASDAQ:PHVS) 2026-05-30 - Seeking Alpha
Pharvaris (PHVS) Holds Near Resistance as Shares Edge Higher on Modest VolumeRetail Driven Moves - The Legal Advocate
Pharvaris Trades Flat as Investors Wait for June Data Update - Bez Kabli
Pharvaris (PHVS) Edges Higher Amid Tight Trading Range, Testing Resistance at $31.61Death Cross - The Legal Advocate
Hereditary angioedema oral drug data headed to European allergy congress - Stock Titan
Pharvaris (PHVS) director Monges sells 9,667 shares, updates ownership - Stock Titan
Pharvaris (PHVS) accounting officer exercises options, sells 7,330 shares - Stock Titan
Pharvaris (PHVS) CFO/CLO Nassif sells 10,000 shares, corrects ownership - Stock Titan
Oppenheimer maintains Pharvaris NV (PHVS) outperform recommendation - MSN
Avoiding Lag: Real-Time Signals in (PHVS) Movement - Stock Traders Daily
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Anna Nijdam proposes sale of 5,501 PHVS shares via Morgan Stanley (PHVS) - Stock Titan
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris (PHVS) technical ops chief sells 8,748 shares in open market - Stock Titan
Pharvaris (PHVS) CCO Souverijns sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
Pharvaris N.V. (PHVS) Fell -5.23% — Is a Recovery Ahead? 2026-05-18{涓偂鍓爣棰榼 - Newser
Pharvaris N.V. (PHVS) Delivers Q1 2026 Beat — EPS $-0.59 vs $-0.73 ExpectedShare Dilution Risk - Newser
The Bull Case For Pharvaris (PHVS) Could Change Following Major Equity Raise And NDA ProgressLearn Why - simplywall.st
Viking Global affiliates hold 3.65M shares of Pharvaris (PHVS) after amendment - Stock Titan
PHVS (NASDAQ: PHVS) reports 10b5-1 sales of 23,333; 2,292 RSUs - Stock Titan
Affiliate files notice to sell 4,667 & 4,137 shares (NASDAQ: PHVS) - Stock Titan
Pharvaris N.V. (PHVS) Q4 2025 Earnings Miss: EPS $-0.72 vs $-0.63 ExpectedEarnings Surprise Report - Newser
Discipline and Rules-Based Execution in PHVS Response - Stock Traders Daily
Why Pharvaris Shares Are Suddenly Sliding Today - TipRanks
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case - Yahoo Finance
Pharvaris (PHVS) CMO reports 226 shares withheld for RSU taxes - Stock Titan
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.57, Implies 49% Upside - TradingView
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.51, Implies 49% Upside - TradingView
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pharvaris Nv-Aktie (PHVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nijdam Anna | Principal Accounting Officer |
Jun 04 '26 |
Sale |
30.87 |
2,670 |
82,425 |
46,275 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):